Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OPINION: Impact Of The TPP On The Pharma Industry

This article was originally published in PharmAsia News

Executive Summary

The final text of the Trans-Pacific Partnership confirms beyond doubt the apprehensions expressed by civil society, academia and the generic industry about new barriers to access to medicines. The TPP has done away with several flexibilities provided under the TRIPS Agreement and the Doha Declaration on Public Health. Though the text mentions “nothing in this [IPR] Chapter limits a Party’s rights and obligations under Article 31 of the TRIPS Agreement,” the TPP Investment Chapter overrides these flexibilities, says D G Shah.

You may also be interested in...



‘Trump Shock’ Rattles Japan But Pharma Plays Wait And See

The surprise decisive victory of Donald Trump in the US election has already been dubbed the "Trump Shock" by the mass media in Japan, where the pharma industry is largely waiting to see whether the new president's actions will match his rhetoric.

‘Trump Shock’ Rattles Japan But Pharma Plays Wait And See

The surprise decisive victory of Donald Trump in the US election has already been dubbed the "Trump Shock" by the mass media in Japan, where the pharma industry is largely waiting to see whether the new president's actions will match his rhetoric.

Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay

Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel